Active Ingredient(s): Daclizumab
FDA Approved: * May 27, 2016
Pharm Company: * BIOGEN
Category: Immunosuppressive

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Zinbryta 150 mg/ml Subcutaneous Injection, Solution
NDC: 0074-0033

Related Brands

Drugs with the same active ingredients

Popular Topics

Zinbryta (daclizumab)

My husband spent seven weeks in the hospital, seriously ill. A major contributing factor is believed to be the Zinbryta ...